Thor Medical | Alpha emitters for cancer therapy Thor Medical is a producer and supplier of alpha-particle emitters for cancer therapy The production process is based on separation of natural occurring radioactive decay products from thorium (Th-232)
Nordic Nanovector to merge with APIM after Betalutin fail Five months after giving up on its lead drug Betalutin for follicular lymphoma, Nordic Nanovector has charted a course forward via a merger with fellow Norwegian biotech APIM Therapeutics
Nordic Nanovector - Carnegie Norway Nordic Nanovector ASA announced 6th of June the signing of an agreement to acquire Thor Medical AS, a privately held company focused on the production of alpha-emitting radionuclides for cancer treatment, in an all-share transaction
Nordic Nanovector to acquire Thor Medical - scatecinnovation. no Nordic Nanovector ASA (OSE: NANOV) and Thor Medical AS, a privately held company focused on the production of alpha-emitting radionuclides for cancer treatment, today announce that they have entered into a definitive share exchange agreement to combine the two companies in an all-share transaction
Nordic Nanovector announces agreement to acquire Thor Medical Nordic Nanovector ASA (OSE: NANOV) and Thor Medical AS, a privately held company focused on the production of alpha-emitting radionuclides for cancer treatment, today announce that they have entered into a definitive share exchange agreement to combine the two companies in an all-share transaction
Nordic Nanovector - Company Profile - Tracxn What does Nordic Nanovector do? Developer of antibody radionuclide conjugates for hematological cancers The company's lead product includes Betalutin, an ARC that comprises a tumor-seeking anti-CD37 antibody conjugated to a low-intensity radionuclide (Lutetium 177) It is used to treat blood cancer non-Hodgkin Lymphoma
Nordic Nanovector Launches Dedicated Area on its Website in Norwegian . . . Issuer Thor Medical ASA Oslo, Norway, 25 November 2022 Nordic Nanovector ASA (OSE: NANOV) ("Nordic Nanovector" or the "Company") has today launched a new dedicated area on its website (www nordicnanovector com) with information in Norwegian for shareholders relating to its proposed merger